Steven C. Gilman

CIK: 0001379970

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (40.0%)

Position reduction

Option Exercises (M)4 (40.0%)

Derivative conversions

Awards (A)2 (20.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

SCYX

SCYNEXIS INC

Director

AKBA

Akebia Therapeutics, Inc.

Director

VCEL

Vericel Corp

Director

Discretionary Trading P&L

Holdings

Transaction History (10 total)

SCYX
SCYNEXIS INC
Jun 26, 2025
Award(A)
Direct
23K shares-
AKBA
Akebia Therapeutics, Inc.
Jun 10, 2025
Award(A)
Direct
35.7K shares-
VCEL
Vericel Corp
Oct 16, 2024
Sale(S)
Direct
5.8K shares at avg. $41.36$241K
VCEL
Vericel Corp
Oct 16, 2024
Exercise(M)
Direct
5.8K shares at avg. $13.05$76K
VCEL
Vericel Corp
Oct 2, 2024
Exercise(M)
Direct
5.8K shares at avg. $13.05$76K
VCEL
Vericel Corp
Oct 2, 2024
Sale(S)
Direct
5.8K shares at avg. $40.35$235K
VCEL
Vericel Corp
Sep 18, 2024
Sale(S)
Direct
5.8K shares at avg. $45.54$266K
VCEL
Vericel Corp
Sep 18, 2024
Exercise(M)
Direct
5.8K shares at avg. $13.05$76K
VCEL
Vericel Corp
Sep 4, 2024
Exercise(M)
Direct
5K shares at avg. $3.74$19K
VCEL
Vericel Corp
Sep 4, 2024
Sale(S)
Direct
5K shares at avg. $48.58$243K

		Type	Shares	Price		Ownership
Jun 26, 2025	SCYX SCYNEXIS INC	Award(A)	23,000	-	-	Direct
Jun 10, 2025	AKBA Akebia Therapeutics, Inc.	Award(A)	35,700	-	-	Direct
Oct 16, 2024	VCEL Vericel Corp	Sale(S)	5,833	$41.36	$241,253	Direct
Oct 16, 2024	VCEL Vericel Corp	Exercise(M)	5,833	$13.05	$76,121	Direct
Oct 2, 2024	VCEL Vericel Corp	Exercise(M)	5,833	$13.05	$76,121	Direct
Oct 2, 2024	VCEL Vericel Corp	Sale(S)	5,833	$40.35	$235,362	Direct
Sep 18, 2024	VCEL Vericel Corp	Sale(S)	5,834	$45.54	$265,680	Direct
Sep 18, 2024	VCEL Vericel Corp	Exercise(M)	5,834	$13.05	$76,134	Direct
Sep 4, 2024	VCEL Vericel Corp	Exercise(M)	5,000	$3.74	$18,700	Direct
Sep 4, 2024	VCEL Vericel Corp	Sale(S)	5,000	$48.58	$242,900	Direct

1-10 of 10 transactions

About GILMAN STEVEN C

GILMAN STEVEN C (SEC CIK 0001379970) files insider reports with the SEC as Director of SCYNEXIS INC (SCYX), Director of Akebia Therapeutics, Inc. (AKBA) and Director of Vericel Corp (VCEL).

Signal8 holds 6 ownership filings by GILMAN STEVEN C, all Form 4s, filed between Sep 5, 2024 and Jun 30, 2025. Those filings report 10 transactions, from Sep 4, 2024 to Jun 26, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on GILMAN STEVEN C's filings is in CAMBRIDGE, MA.

Recent filings by GILMAN STEVEN C

Jun 26, 2025: Grant or award of SCYX shares (Form 4, code A).
Jun 10, 2025: Grant or award of AKBA shares (Form 4, code A).
Oct 16, 2024: Open-market sale of VCEL shares (Form 4, code S).
Oct 16, 2024: Option exercise of VCEL shares (Form 4, code M).
Oct 2, 2024: Option exercise of VCEL shares (Form 4, code M).

Other insiders filing for SCYNEXIS INC (SCYX)

Burke Steven Keith, Director
Subramanian Sanjay, Chief Financial Officer
Tinmouth Brian Philippe, Officer
Macdonald Guy, Officer
ANIDO ARMANDO, Officer
HASTINGS DAVID C, Officer

How to read Form 4 transaction codes